Heparin Anticoagulation in Septic Shock
common.study.values.description
“Heparin Anticoagulation in Septic Shock”
This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Unfractionated heparin
UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis acco ...read more on ClinicalTrials.org
Venous thromboprophylaxis (VTE)
May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
participant.views.study.view.additional
participant.views.study.view.scientific-title
Heparin AnticoaguLation to Improve Outcomes in Septic Shock: The HALO International Phase II RCT
common.study.values.clinical-trial-id
NCT03378466
participant.views.study.view.id
9aA47e
